亚洲最大福利网站_4hu四虎永久网址_麻豆国产原创_国产成人av一区二区

FDA approves Sanofi/Regeneron colon cancer drug
date:Aug 06, 2012
The infused medicine, to be taken in combination with standard chemotherapy, will compete with Roche Holding AG's Avastin and Bristol-Myers Squibb Co's Erbitux.


Industry analysts say they expect Zaltrap to win peak annual sales of perhaps $300 million to $400 million, well below the widely used older treatments.
Patients taking Zaltrap in a large clinical trial, in combination with a standard chemotherapy combination regimen called FOLFIRI, lived an average of 13.5 months, compared with 12 mon

12/22 06:23